InChI=1S/Fe.H2O4S.H2O/c;1-5(2,3)4;/h;(H2,1,2,3,4);1H2/q+2;;/p-2 |
XBDUTCVQJHJTQZ-UHFFFAOYSA-L |
O.[Fe++].[O-]S([O-])(=O)=O |
|
reducing agent
The element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.
|
|
nutraceutical
A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
anti-anaemic agent
A compound which increases either the number of red cells or the amount of haemoglobin in the blood.
|
|
View more via ChEBI Ontology
iron(2+) sulfate—water (1/1)
|
dried ferrous sulfate
|
ChEBI
|
exsiccated ferrous sulfate
|
ChEBI
|
exsiccated iron(2+) sulfate
|
ChEBI
|
ferrous sulfate (dried)
|
ChEBI
|
ferrous sulfate monohydrate
|
ChemIDplus
|
FeSO4·H2O
|
ChEBI
|
iron(II) sulfate monohydrate
|
ChemIDplus
|
Feromax
|
ChEBI
|
Feroritard
|
ChEBI
|
Ferro-Gradumet
|
ChEBI
|
Fespan
|
ChEBI
|
Tetucur
|
KEGG DRUG
|
11322535
|
Reaxys Registry Number
|
Reaxys
|
17375-41-6
|
CAS Registry Number
|
ChemIDplus
|
Morrison J, Bell J, Chang AM, Larkin PK (1977) A comparative trial of haematinic supplements in pregnancy. The Medical journal of Australia 1, 482-484 [PubMed:865369] [show Abstract] Four haematinic supplements--Slow-Fe, FGF, Ferro-Gradumet and Ferro-Grad tfolic--were prospectively studied in 103 healthy pregnant patients. Significant differences in the mean cell counts, haematocrit values, haemoglobin levels, iron-binding capacities and serum folate levels were noted. The changes paralleled the elemental iron present in the compount. In this series, side effects principally vomiting and constipation, were more frequent in the lower dose iron group. Form both the haematological status aspect and the lack of side effects, Ferro-Grad Folic and Ferro-Gradumet were superior to both FGF and Slow-Fe (old formulation). | Luntz GR, Bogie W (1975) A comparative trial of a new, fast-release iron capsule ("Eryfer") and a slow-release tablet ('Ferro-Gradumet') in iron-deficiency anaemia. Current medical research and opinion 3, 145-150 [PubMed:1149482] [show Abstract] Sixty hospitalised patients receiving treatment for tuberculosis, diabetes or chronic bronchitis and who had iron-deficiency anaemia (Hb levels less than 12.5g./100 ml.) were entered in a between-patient comparative study of a new, fast-release iron capsule ('Eryfer') and a standard slow-release iron tablet ('Ferro-Gradumet'). Patients were allocated to either drug at random and recived either 2 capsules (100 mg. elemental iron) or 1 tablet (105 mg. elemental iron) daily for 30 days. Haemoglobin levels and packed cell volume were measured before and at the end of the trial period. The results, analysed in 57 patients (28 on 'Eryfer' and 29 on the slow-release iron) indicate that treatment with 'Eryfer' produced a significantly more predictable response in haemoglobin regeneration, the response being dependent on the initial haemoglobin level. Both treatments, however, produced a highly significant increase in haemoglobin levels in the patients (mean increas: 'Eryfer' 1.09 g. and slow-release iron 0.76 g.). No side-effects were recorded with either treatment. |
|